검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ATG (rabbit anti-thymocyte globulin, rabbit anti-thymocyte globulin (ATG)) Sumitomo Pharma Switzerland GmbH·Chronic Myeloproliferative Disorde… 95 trials |
|---|---|
Overview Program | rabbit anti-thymocyte globulin (ATG) |
Overview Company | Sumitomo Pharma Switzerland GmbH |
Overview Modality | ANTIBODY |
Overview Target | Chronic Myeloproliferative Disorders |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting RCC-associated minor histocompatibility antigen |
MoA Biomarker | biomarkers |
PK/PD Species | Rabbit, Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | A new paradigm in Parkinson's disease: kidney-origin α-synuclein pathology driven by PKC signaling and aurothioglucose.. Protein Kinase C (PKC), a zinc-dependent signaling enzyme essential for cellular homeostasis, has recently emerged as a critical regulator of α-synuclein (α-Syn) dynamics beyond the central nervous system. Growing evidence suggests that PKC may contribute to &#… |
Clinical OS | 49 |
Clinical Result source | ClinicalTrials.gov NCT01295710 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ATG (rabbit anti-thymocyte globulin, rabbit anti-thymocyte globulin (ATG)) Sumitomo Pharma Switzerland GmbH·Chronic Myeloproliferative Disorde… 95 trials |
|---|---|
Overview Program | rabbit anti-thymocyte globulin (ATG) |
Overview Company | Sumitomo Pharma Switzerland GmbH |
Overview Modality | ANTIBODY |
Overview Target | Chronic Myeloproliferative Disorders |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | targeting RCC-associated minor histocompatibility antigen |
MoA Biomarker | biomarkers |
PK/PD Species | Rabbit, Human |
PK/PD Animal (cat.) | Human |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit, Human |
Toxicology Animal (cat.) | Human |
Toxicology Major finding | A new paradigm in Parkinson's disease: kidney-origin α-synuclein pathology driven by PKC signaling and aurothioglucose.. Protein Kinase C (PKC), a zinc-dependent signaling enzyme essential for cellular homeostasis, has recently emerged as a critical regulator of α-synuclein (α-Syn) dynamics beyond the central nervous system. Growing evidence suggests that PKC may contribute to &#… |
Clinical OS | 49 |
Clinical Result source | ClinicalTrials.gov NCT01295710 |
Clinical Data Tier / Score | A · 35 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교